AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
225.55
+2.53 (1.14%)
Feb 2, 2026, 3:23 PM EST - Market open
AbbVie Employees
AbbVie had 55,000 employees as of December 31, 2024. The number of employees increased by 5,000 or 10.00% compared to the previous year.
Employees
55,000
Change (1Y)
5,000
Growth (1Y)
10.00%
Revenue / Employee
$1,084,436
Profits / Employee
$42,691
Market Cap
398.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | 0 | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| Eli Lilly and Company | 47,000 |
ABBV News
- 3 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 4 days ago - 10 Highest Rated Dividend Kings For Generations Of Income - Seeking Alpha
- 4 days ago - AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships - PRNewsWire
- 5 days ago - Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine - PRNewsWire
- 5 days ago - US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Reuters
- 6 days ago - The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator - Business Wire
- 7 days ago - Best Dividend Kings: January 2026 - Seeking Alpha
- 17 days ago - AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - PRNewsWire